About the company
Crescendo Biologics is a private, clinical stage immuno-oncology company developing novel, targeted T cell enhancing Humabody® therapeutics based on a unique, patent protected, discovery platform.
Leading its proprietary pipeline, Crescendo has developed CB307, a novel half-life extended CD137 x PSMA Humabody. CB307 is designed to achieve a longer lasting anti-cancer effect whilst avoiding systemic toxicity, and the clinical programme for CB307 is underway in patients with PSMA positive solid tumours (NCT04839991).
Theodora Harold
CEO
Crescendo Biologics are looking to connect with:
Pharmaceutical Companies; Biotechnology Companies; Investors; Clinical Trial Investigators.
Interested in connecting with Crescendo Biologics?
Submit enquiry
Crescendo Biologics are looking to connect with:
Pharmaceutical Companies; Biotechnology Companies; Investors; Clinical Trial Investigators.
Id voluptate laborum quibusdam repudiandae debitis quam. Consequatur voluptas dicta sapiente eos magnam aut. At non dignissimos facere unde suscipit quis molestias.Accreditation
